

# Vaccinations and child survival WG

**Focus: monitoring childhood interventions including routine services and campaigns => changes in policy**

**Why is that necessary?**

Current focus in International Health is

- Prevention of specific diseases (malaria, rota, measles etc) and deficiencies (vitamin A, iron etc)
- Effects assumed to be good and proportional to the burden of disease
- Effects assumed to be the same for girls and boys
- Effects assume to be independent

# Vaccinations and child survival WG

Focus: monitoring childhood interventions including routine services and campaigns => changes in practice


However, current interventions in International Health:

- Effects on mortality can be far better than they should
- Effects on mortality can be negative – increasing mortality
- Effects often differ completely for girls and boys – suggesting that to treat girls and boys optimally you may have to treat them differently
- Interventions often interact – neutralising or reversing effects of other interventions

INDEPTH is in a unique position to document the "real effect" and turn them into policy

# Before-after measles vaccination:


Annual mortality rates in African community studies in the 1970s and 1980s



Measles is not 50% of deaths – Why this effect of Measles vaccine?  
Does not fit current concepts => *a beneficial non-specific effect*

# Vitamin A supplementation at birth and infant mortality by sex

Normal-birth-weight:




Meta-estimates of the two RCTs

Boys: 0.80 (0.58-1.09)

Girls: 1.41 (1.04-1.90)


P for interaction=0.01

Low-birth-weight:



P=0.04 for interaction

# MV at 4+9mo vs No vac(DTP3)+MV at 9mo by Vitamin A-at-birth status



**Vitamin A may have a fundamental impact on the NSEs**

## Vaccinations and child survival:

These effects may be unbelievable!

But they are there and we better face them:

- High-titre MV 2-fold increased mortality for girls
- Vitamin A interact negatively with DTP in Bissau and Ghana
- RCT of BCG 45% reduction in neonatal mortality
- RCT of BCG revaccination after DTP booster 3-fold reduction
- RCT of MV at 4+9 months 50% reduction in mortality between 4 mo and 3 years of age

This is a huge opportunity for INDEPTH – we are the only one who can measure “real life” effects for current interventions and all the new vaccines in the pipeline

# Vaccinations and child survival: What is required?

We need *better data* on vaccination and other childhood interventions and campaigns

- Few sites have regular data on routine interventions and campaigns
- Data have often been analysed wrongly => we need better analytical methods

We need *young scientists* at the centres who can collect and analyse such data

=> These needs have defined the WG agenda

# WG: Vaccinations and child survival

- What has happened 2007-2009
  - Centre visits – Nouna; Kilifi; Navrongo; Ballabgarh, Vadu, Rufiji
  - 2008: Small grants from Indepth/DANIDA =>
  - April 2008: Workshop on non-specific effects of vaccines in London (organised by Peter Smith). Resulted in 3 papers =>
    - Data Collection (TMIH)
    - Analytical issues (TMIH)
    - Potential randomised trials of non-specific effects (PIDJ)
  - 2009 Applications to DANIDA, EDCTP, EU-FP7
  - 2010: Danida – 1.3 mill € for research training network and EU-FP7 possibly 3 mill € for multisite study; EDCTP: 0



# Vaccinations and child survival: Research training network

**PhD proposal to Danida: Monitoring the impact of childhood interventions on child survival and morbidity (Ballabgarh, Navrongo, Nouna, Nairobi, Kintampo, Bandim)**

**To support data collection and analysis of impact of routine vaccinations and other interventions in childhood**

**Common data collection methodology: special teams for data collection; children under 2 or 3 years of age, 3-4 yearly rounds, birth form, verbal autopsy, SES and nutritional status, and documenting other interventions (vitamin A etc) and campaign**

**Improve routine data collection on vaccinations => to facilitate observational studies and decide on priority trials**

**(we can come back)**

# Vaccinations and child survival:

## EU: Multicentre study

**EU proposal: "Optimising the impact and cost-effectiveness of existing child health intervention programmes for vaccines and micronutrients in low-income countries" (Navrongo, Nouna, Bandim)**

**To support common data collection methodology and analysis of the impact of routine vaccinations and other interventions in childhood**



**Conduct a multicentre trial of early measles vaccination at 4 months**

**Develop a methodology to assess "real life" effects of health programmes and evaluate the cost effectiveness and suggest possible modifications => conduct new trials**

# WG: Vaccinations and child survival

- **Analysis of existing data 2007-2010**
  - Farafenni => Routine vaccinations and child mortality (Vaccine 2007)
  - Navrongo => Vaccines and vitamin A (Am J Clin Nut 2009)
  - Draft: Paul Welaga: Non-specific of routine vaccinations: testing the hypothesis with data from Navrongo
  - Started analysis of the first cross site paper : The impact of nutritional status on time to vaccination (Vadu, Bissau, Malawi)
  - Been promised more data from Vadu, Matlab, Rufiji – (hope to report next year)

# Analysis from Farafenni (Vaccine 2007)




**Showed the same changes in relative female-male mortality as in Bissau**

**DTP age (3-8 months) – higher female than male mortality**

**MV age (9-17 months) – lower female than male mortality**

# Navrongo RCT, reanalysis

Mortality Ratio for VAS vs placebo



The VAS effect differed in children with (N=6,656) and without (N=5,066) a health card - due to differential effect of VAS in girls (P<0.01)

Benn et al, Am J Clin Nut 2009

**WG: Vaccinations and child survival**

**PhD network: Ballabgarh, Navrongo, Nouna,  
Nairobi, Kintampo, Bandim**

**Multi-centre trial: Navrongo, Nouna, Bandim**

**Analysis of existing data: Navrongo, Vadu,  
Matlab, Rufiji – we can do a lot more with  
existing data**

**Interested parties: Iganga, Gambia, Dodowa,  
Ifakara?**

**Other initiatives?**

**Working group meeting Wedn 16-17.30**

## Vaccinations and child survival:



The area is obviously controversial because it questions many of the current assumptions

However, it also has huge potential for improving child survival

I hope more INDEPTH centres will pursue the area

# 1986-90 RCT High-titre MV 2003-2009 RCT two-doses MV

BISSAU 1986-90, EZ-HT



- EZ high-titre MV was fully protective against measles => negative non-specific effect
- Two-dose standard MV at 4½ and 9 mo was fully protective against measles => beneficial non-specific effect



# Non-specific effects of vaccine on child survival



**Real  
life?**

# Vitamin A and early measles vaccination: Mortality between 4 and 36 months after measles vaccination at 4 months

	Deaths/N		Mortality rate ratio
	Vitamin A at birth	Placebo	
Boys	20/526	4/350	3.33 (1.2-9.7)
Girls	13/496	5/329	1.72 (0.6-4.8)
All	33/1022	9/679	2.44 (1.2-5.1)

## Beneficial nonspecific effects: Early MV at 4+9 mo vs MV at 9 mo

Morality rate between 4 and 36 months (deaths/pyrs)			Mortality rate ratio
	MV at 4 + 9 months	MV at 9 months	
Boys	1.0 (12/1254)	1.7 (40/2300)	0.56 (0.29-1.06)
Girls	1.1 (13/1199)	2.3 (56/2402)	0.47 (0.26-0.86)
All	1.0 (25/2453)	2.0 (96/4703)	0.50 (0.32-0.78)

Only 10% due to prevention of measles infection; censoring for measles the MRR is 0.55 (0.35-0.87)

# Vaccinations and child survival: Campaigns for a cohort born 2003-6

- BCG vaccination for all children born at the national hospital since 2002
- Vitamin A and missing vaccination campaign in 2003
- OPV campaigns in 2004 and 2005
- Vitamin A campaigns every year 2004, 2005, 2006 twice, 2007 twice, 2008 twice, 2009 twice
- Measles vaccination campaign in 2006 for all children aged 6 months to 15 years
- Measles vaccination campaign in 2009 for all children aged 9 months to 5 years of age
- Bed net distribution 2006 and 2007
- Bed net impregnation 2006 and 2007
- De-worming every year 2006-2009

**WG: Vaccinations and child survival  
DANIDA application for 3 mill \$ for this  
network**

**Response: Science okay – you can get 2 mill if  
you can get the last mill elsewhere**

**We are trying to apply to EDTCP together  
with Heidelberg**

**If this is not feasible we have to have an  
alternative "low cost" solution**